FDA Approves Combined Dapagliflozin/Saxagliptin for Adults With Type 2 Diabetes

Date: 
March, 2017
February 28, 2017. The US Food and Drug Administration has approved a once-daily formulation of dapagliflozin 10 mg and saxagliptin 5 mg (trade name Qtern). Qtern provides dual antihyperglycemic therapy to patients with type 2 diabetes by combining a sodium-glucose cotransporter-2 inhibitor and dipeptidyl peptidase-4 inhibitor in a single daily tablet. Click here for full article